COMPASS Pathways

Private Company

Company Overview

COMPASS Pathways is a life sciences company that aims to accelerate patient access to evidence-based innovations in mental health.

The company recently launched a massive late-stage clinical study across Europe and North America to evaluate psilocybin in patients with treatment-resistant depression. With a Breakthrough Therapy designation from the FDA, the company hopes to accelerate the drug development process. The company also recently filed for a patent application.

The Breakthrough Therapy designation represents a significant milestone for psilocybin therapy and research. With about 100 million individuals around the world suffering from treatment-resistant depression, there's a significant unmet medical need.

Management Team


George Goldsmith
Chairman, CEO and Co-Founder

Ekaterina Malievskaia MD, MScPH
Co-Founder & Chief Innovation Officer

Lars Christian Wilde
Co-Founder, President, Chief Business Officer

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.